Wall Street brokerages expect PDS Biotechnology Co. (NASDAQ:PDSB) to post ($0.20) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for PDS Biotechnology’s earnings, with estimates ranging from ($0.23) to ($0.17). PDS Biotechnology reported earnings per share of ($0.39) in the same quarter last year, which suggests a positive year-over-year growth rate of 48.7%. The company is scheduled to issue its next earnings report on Wednesday, May 12th.
According to Zacks, analysts expect that PDS Biotechnology will report full year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.44) to ($0.65). For the next year, analysts anticipate that the firm will post earnings of ($0.81) per share, with EPS estimates ranging from ($0.90) to ($0.60). Zacks’ earnings per share calculations are an average based on a survey of research firms that that provide coverage for PDS Biotechnology.
PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Thursday, March 18th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02.
PDSB traded down $0.08 during trading hours on Thursday, hitting $5.58. 26,048 shares of the stock were exchanged, compared to its average volume of 1,596,069. The stock has a 50-day simple moving average of $4.64 and a 200-day simple moving average of $3.09. PDS Biotechnology has a 12 month low of $0.66 and a 12 month high of $7.30. The stock has a market cap of $124.22 million, a price-to-earnings ratio of -3.66 and a beta of 2.70.
Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in PDS Biotechnology by 624.5% during the 3rd quarter. BlackRock Inc. now owns 104,415 shares of the company’s stock valued at $244,000 after purchasing an additional 90,002 shares during the period. Minot Wealth Management LLC acquired a new position in PDS Biotechnology during the 4th quarter valued at about $105,000. Renaissance Technologies LLC boosted its stake in PDS Biotechnology by 5.7% during the 4th quarter. Renaissance Technologies LLC now owns 828,721 shares of the company’s stock valued at $1,773,000 after purchasing an additional 44,864 shares during the period. Ellis Investment Partners LLC boosted its stake in PDS Biotechnology by 693.3% during the 4th quarter. Ellis Investment Partners LLC now owns 17,850 shares of the company’s stock valued at $38,000 after purchasing an additional 15,600 shares during the period. Finally, Newman & Schimel LLC acquired a new position in PDS Biotechnology during the 4th quarter valued at about $25,000. 14.80% of the stock is owned by institutional investors and hedge funds.
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.
Read More: What is an Initial Coin Offering (ICO)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.